Singulex withdraws $70 million IPO
Singulex, which provides diagnostic testing for cardiovascular disease in a non-acute setting, withdrew its plans for an initial public offering on Friday citing poor market conditions. Singulex had postponed its planned $70 million offering in November. The Alameda, CA-based company was founded in 1997 and booked $38 million in sales for the 12 months ended 6/30/2012. UBS Investment Bank and Piper Jaffray were set to be the joint bookrunners on the deal.